MiR-144 inhibits cell proliferation of renal cell carcinoma by targeting MTOR

Abstract

MicroRNAs (miRNAs) modulate the expression of tumorigenesis-related genes and play important roles in the development of various types of cancers. It has been reported that miR-144 is dysregulated and involved in multiple malignant tumors, but its role in renal cell carcinoma (RCC) remains elusive. In this study, we demonstrated miR-144 was significantly downregulated in human RCC. The decreased miR-144 correlated with tumor size and TNM stage. Moreover, overexpression of miR-144 in vitro suppressed RCC cell proliferation and G2 transition, which were reversed by inhibition of miR-144. Bioinformatic analysis predicted that mTOR was a potential target of miR-144, which was further confirmed by dual luciferase reporter assay. Additionally, the examination of clinical RCC specimens revealed that miR-144 was inversely related to mTOR. Furthermore, knocking down mTOR with siRNA had the same biological effects as those of miR-144 overexpression in RCC cells, including cell proliferation inhibition and S/G2 cell cycle arrest. In conclusion, our results indicate that miR-144 affects RCC progression by inhibiting mTOR expression, and targeting miR-144 may act as a novel strategy for RCC treatment.

Keywords

renal cell carcinoma (RCC) / miR-144 / mTOR / proliferation

References

[1] SiegelR, MaJ, ZouZ, et al. . Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1): 9-29 PMID: 24399786

[2] MotzerRJ, MolinaAM. Targeting renal cell carcinoma. J Clin Oncol, 2009, 27(20): 3274-3276 PMID: 19451422

[3] RussoP. Renal cell carcinoma: presentation, staging, and surgical treatment. Semin Oncol, 2000, 27(2): 160-176 PMID: 10768595

[4] BartelDP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116(2): 281-297 PMID: 14744438

[5] WinterJ, JungS, KellerS, et al. . Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol, 2009, 11(3): 228-234 PMID: 19255566

[6] FuYF, DuTT, DongM, et al. . Mir-144 selectively regulates embryonic alpha-hemoglobin synthesis during primitive erythropoiesis. Blood, 2009, 113(6): 1340-1349 PMID: 18941117

[7] RasmussenKD, SimminiS, Abreu-GoodgerC, et al. . The miR-144/451 locus is required for erythroid homeostasis. J Exp Med, 2010, 207(7): 1351-1358 PMID: 20513743 PMCID: 2901075

[8] FuX, HuangX, LiP, et al. . 7-Ketocholesterol inhibits isocitrate dehydrogenase 2 expression and impairs endothelial function via microRNA-144. Free Radic Biol Med, 2014, 71(6): 1-15 PMID: 24642088

[9] FanJY, YangY, XieJY, et al. . MicroRNA-144 mediates metabolic shift in ovarian cancer cells by directly targeting Glut1. Tumour Biol, 2015

[10] LiuJ, XueH, ZhangJ, et al. . MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. J Exp Clin Cancer Res, 2015, 34(1): 35 PMID: 25927670 PMCID: 4417226

[11] MatsushitaR, SekiN, ChiyomaruT, et al. . Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer. Br J Cancer, 2015, 113(2): 282-289 PMID: 26057453

[12] LovatF, ValeriN, CroceCM. MicroRNAs in the pathogenesis of cancer. Semin Oncol, 2011, 38(6): 724-733 PMID: 22082758

[13] PoudelS, SongJ, JinEJ, et al. . Sulfuretin-induced miR-30C selectively downregulates cyclin D1 and D2 and triggers cell death in human cancer cell lines. Biochem Biophys Res Commun, 2013, 431(3): 572-578 PMID: 23318178

[14] BudhuA, JiaHL, ForguesM, et al. . Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology, 2008, 47(3): 897-907 PMID: 18176954

[15] ZhaoLY, YaoY, HanJ, et al. . miR-638 suppresses cell proliferation in gastric cancer by targeting Sp2. Dig Dis Sci, 2014, 59(8): 1743-1753 PMID: 24623314

[16] AravalliRN, SteerCJ, CressmanEN. Molecular mechanisms of hepatocellular carcinoma. Hepatology, 2008, 48(6): 2047-2063 PMID: 19003900

[17] ZhaiJ, QuS, LiX, et al. . miR-129 suppresses tumor cell growth and invasion by targeting PAK5 in hepatocellular carcinoma. Biochem Biophys Res Commun, 2015, 464(1): 161-167 PMID: 26116538

[18] KasinskiAL, KelnarK, StahlhutC, et al. . A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene, 2015, 34(27): 3547-3555 PMID: 25174400 PMCID: 4345154

[19] KelnarK, PeltierHJ, LeatherburyN, et al. . Quantification of therapeutic miRNA mimics in whole blood from nonhuman primates. Anal Chem, 2014, 86(3): 1534-1542 PMID: 24397447 PMCID: 3982984

[20] SiML, ZhuS, WuH, et al. . miR-21-mediated tumor growth. Oncogene, 2007, 26(19): 2799-2803 PMID: 17072344

[21] ChenS, LiP, LiJ, et al. . MiR-144 inhibits proliferation and induces apoptosis and autophagy in lung cancer cells by targeting TIGAR. Cell Physiol Biochem, 2015, 35(3): 997-1007 PMID: 25660220

[22] YuH, SunH, BaiY, et al. . MEF2D overexpression contributes to the progression of osteosarcoma. Gene, 2015, 563(2): 130-135 PMID: 25814384

[23] CaoT, LiH, HuY, et al. . miR-144 suppresses the proliferation and metastasis of hepatocellular carcinoma by targeting E2F3. Tumour Biol, 2014, 35(11): 10759-10764 PMID: 25073510

[24] GuanH, LiangW, XieZ, et al. . Down-regulation of miR-144 promotes thyroid cancer cell invasion by targeting ZEB1 and ZEB2. Endocrine, 2015, 48(2): 566-574 PMID: 24968735

[25] GuertinDA, SabatiniDM. Defining the role of mTOR in cancer. Cancer Cell, 2007, 12(1): 9-22 PMID: 17613433

[26] XiongY, YepuriG, ForbitehM, et al. . ARG2 impairs endothelial autophagy through regulation of MTOR and PRKAA/AMPK signaling in advanced atherosclerosis. Autophagy, 2014, 10(12): 2223-2238 PMID: 25484082 PMCID: 4502672

[27] RibbackS, CiglianoA, KroegerN, et al. . PI3K/AKT/ mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men. Oncotarget, 2015, 6(15): 13036-13048 PMID: 25948777 PMCID: 4536997

[28] BaileyST, ZhouB, DamrauerJS, et al. . mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. PLoS One, 2014, 9(9): e104413 PMID: 25180793 PMCID: 4152178